Pyc Therapeutics Ltd has released a press release.
RP11 Clinical Trial Dosing Completed in Cohort 4
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Successful GLP Tox Studies in Second Blinding Eye Disease
- Presentation of RP11 Clinical Trial Data at ARVO Conference
- RP11 Drug Candidate Progressing to Mid-Stage Human Trials
- Kidney Disease Drug Candidate Progressing to Human Trials
- $74.6 Million Extension of Cash Runway
Later from PYC Therapeutics
- PMS Drug Candidate Effective In Human Brain Cells
- RP11 Drug Candidate Safe and Well Tolerated
- Commencement of RP11 Multiple Dose Trial
- Initial Dosing Completed in Cohort 1 of RP11 MAD Study
- Extension of RP11 Single Dose Study Into Multiple Dose Study
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics